118 related articles for article (PubMed ID: 21825987)
21. Preselective gene therapy for Fabry disease.
Qin G; Takenaka T; Telsch K; Kelley L; Howard T; Levade T; Deans R; Howard BH; Malech HL; Brady RO; Medin JA
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3428-33. PubMed ID: 11248095
[TBL] [Abstract][Full Text] [Related]
22. [Fabry disease].
Kantola I; Penttinen M; Nuutila P; Viikari J
Duodecim; 2012; 128(7):729-39. PubMed ID: 22612023
[TBL] [Abstract][Full Text] [Related]
23. Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey.
Ramaswami U; Parini R; Pintos-Morell G; Kalkum G; Kampmann C; Beck M;
Clin Genet; 2012 May; 81(5):485-90. PubMed ID: 21457233
[TBL] [Abstract][Full Text] [Related]
24. [Fabry disease: clinic and enzymatic diagnosis of homozygous and heterozygous. New therapeutic prospects].
Peces R; Olea T
Nefrologia; 2002; 22(6):540-6. PubMed ID: 12516287
[TBL] [Abstract][Full Text] [Related]
25. [Peripheral neuropathy in Anderson-Fabry disease: its physiology, evaluation and treatment].
Politei JM; Pagano MA
Rev Neurol; 2004 May 16-31; 38(10):979-83. PubMed ID: 15175982
[TBL] [Abstract][Full Text] [Related]
26. Fibrosis: a key feature of Fabry disease with potential therapeutic implications.
Weidemann F; Sanchez-Niño MD; Politei J; Oliveira JP; Wanner C; Warnock DG; Ortiz A
Orphanet J Rare Dis; 2013 Aug; 8():116. PubMed ID: 23915644
[TBL] [Abstract][Full Text] [Related]
27. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
Jung SC; Han IP; Limaye A; Xu R; Gelderman MP; Zerfas P; Tirumalai K; Murray GJ; During MJ; Brady RO; Qasba P
Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2676-81. PubMed ID: 11226298
[TBL] [Abstract][Full Text] [Related]
28. Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy.
Vedder AC; Cox-Brinkman J; Hollak CE; Linthorst GE; Groener JE; Helmond MT; Scheij S; Aerts JM
Mol Genet Metab; 2006 Nov; 89(3):239-44. PubMed ID: 16765076
[TBL] [Abstract][Full Text] [Related]
29. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
Breunig F; Wanner C
J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
[TBL] [Abstract][Full Text] [Related]
30. [Fabry's disease (alpha-galactosidase-A deficiency): recent therapeutic innovations].
Germain DP
J Soc Biol; 2002; 196(2):183-90. PubMed ID: 12360747
[TBL] [Abstract][Full Text] [Related]
31. Long time enzyme replacement therapy stabilizes obstructive lung disease and alters peripheral immune cell subsets in Fabry patients.
Odler B; Cseh Á; Constantin T; Fekete G; Losonczy G; Tamási L; Benke K; Szilveszter B; Müller V
Clin Respir J; 2017 Nov; 11(6):942-950. PubMed ID: 26763180
[TBL] [Abstract][Full Text] [Related]
32. [Renal biopsies in Fabry disease: a multicenter French study].
Noël LH; Laurent B; Grünfeld JP
Nephrol Ther; 2012 Nov; 8(6):433-8. PubMed ID: 22591703
[TBL] [Abstract][Full Text] [Related]
33. Small fiber neuropathy in Fabry disease.
Biegstraaten M; Hollak CE; Bakkers M; Faber CG; Aerts JM; van Schaik IN
Mol Genet Metab; 2012 Jun; 106(2):135-41. PubMed ID: 22497776
[TBL] [Abstract][Full Text] [Related]
34. Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment.
Politei JM; Bouhassira D; Germain DP; Goizet C; Guerrero-Sola A; Hilz MJ; Hutton EJ; Karaa A; Liguori R; Üçeyler N; Zeltzer LK; Burlina A
CNS Neurosci Ther; 2016 Jul; 22(7):568-76. PubMed ID: 27297686
[TBL] [Abstract][Full Text] [Related]
35. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel.
Burlina AP; Sims KB; Politei JM; Bennett GJ; Baron R; Sommer C; Møller AT; Hilz MJ
BMC Neurol; 2011 May; 11():61. PubMed ID: 21619592
[TBL] [Abstract][Full Text] [Related]
36. Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy.
Salviati A; Burlina AP; Borsini W
Neurol Sci; 2010 Jun; 31(3):299-306. PubMed ID: 20300794
[TBL] [Abstract][Full Text] [Related]
37. Quality of life in patients with Fabry disease: a systematic review of the literature.
Arends M; Hollak CE; Biegstraaten M
Orphanet J Rare Dis; 2015 Jun; 10():77. PubMed ID: 26076709
[TBL] [Abstract][Full Text] [Related]
38. Synchronous presentation of monoclonal gammopathy and Fabry nephropathy; diagnostic renal biopsy obviates initiation of myeloma therapy.
Pokuri VK; Xu B; Neppalli V; Czyzyk J; Berenji F; Holstein SA; McCarthy PL
Ann Hematol; 2015 Jun; 94(6):1067-8. PubMed ID: 25666077
[No Abstract] [Full Text] [Related]
39. Fabry disease: will markers of early disease enable early treatment and better outcomes?
Hughes DA
Curr Opin Cardiol; 2016 Jul; 31(4):434-9. PubMed ID: 27205888
[TBL] [Abstract][Full Text] [Related]
40. Pathophysiology and assessment of neuropathic pain in Fabry disease.
Schiffmann R; Scott LJ
Acta Paediatr Suppl; 2002; 91(439):48-52. PubMed ID: 12572843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
